BTIG Initiates Coverage On Bicara Therapeutics with Buy Rating, Announces Price Target of $28
Benzinga Newsdesk 10 months ago
NewsPrice TargetInitiationAnalyst Ratings
BTIG analyst Jeet Mukherjee initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and announces Price Target of $28.
BTIG analyst Jeet Mukherjee initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Buy rating and announces Price Target of $28.